NEWS
Norameda’s Commitment to Advancing Rare Disease Treatment
Rare diseases present unique challenges in diagnosis, treatment, and patient care. As a company dedicated to improving healthcare, Norameda continues to prioritize rare diseases by expanding its portfolio of innovative medicines and strengthening partnerships with...
Norameda Achieved the EcoVadis Committed Badge – A Step Towards a More Sustainable Future
We are thrilled to announce that UAB Norameda has been awarded the EcoVadis Committed badge, marking a significant milestone in our journey toward sustainability. This recognition is a testament to our efforts in aligning business practices with environmental, social,...
Results to be proud of: increase of Norameda’s profit by 130 per cent
Despite the challenging market conditions, Norameda's 2023 performance was a testament to its resilience. The company not only managed to maintain its revenue at a healthy 7% increase compared to 2022 (28.3m vs 26.3m) but also saw a significant 130% growth in profits....
New Price List for Reimbursable Medicines in Lithuania – Norameda’s Assessment
The updated price list for reimbursable medicines came into force in Lithuania in July and has received mixed reactions. Ministry of Health's Perspective According to the Ministry of Health of Lithuania, the new mechanism for selecting reimbursable medications was...